# CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be

- a) a guide for reporting for authors of RCTs,
- b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (non-pharmacologic treatment) items.

Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red \*.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED).

Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF \_AND\_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):

Eysenbach G, CONSORT-EHEALTH Group

CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions

J Med Internet Res 2011;13(4):e126

URL: http://www.jmir.org/2011/4/e126/

### CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Page 2 of 41

doi: 10.2196/jmir.1923 PMID: 22209829			
* Required			
<b>Your name</b> * First Last			
Derek Satre			
Primary Affiliation (short), City, Country *			
University of Toronto, Toronto, Canada			
University of California, S			
Your e-mail address *			
abc@gmail.com			
derek.satre@ucsf.edu			
Title of your manuscript *			
Provide the (draft) title of your manuscript.			
	iof		
A Digital Tool to Promote Alcohol and Drug Use Screening, Bri Intervention, and Referral to Treatment Skill Translation: A Mol App Development and Randomized Controlled Trial Protocol	ief bile		
A Digital Tool to Promote Alcohol and Drug Use Screening, Bri Intervention, and Referral to Treatment Skill Translation: A Mol	ief bile		
A Digital Tool to Promote Alcohol and Drug Use Screening, Bri Intervention, and Referral to Treatment Skill Translation: A Mol	ief bile		
A Digital Tool to Promote Alcohol and Drug Use Screening, Bri Intervention, and Referral to Treatment Skill Translation: A Mol App Development and Randomized Controlled Trial Protocol	ief bile		e
A Digital Tool to Promote Alcohol and Drug Use Screening, Bri Intervention, and Referral to Treatment Skill Translation: A Mol App Development and Randomized Controlled Trial Protocol	bile	fill in this form	)
A Digital Tool to Promote Alcohol and Drug Use Screening, Bri Intervention, and Referral to Treatment Skill Translation: A Mol App Development and Randomized Controlled Trial Protocol	bile	fill in this form	
A Digital Tool to Promote Alcohol and Drug Use Screening, Bri Intervention, and Referral to Treatment Skill Translation: A Mol App Development and Randomized Controlled Trial Protocol  Article Preparation Status/Stage *  At which stage in your article preparation are you currently (at the	ne time you	fill in this form	)
A Digital Tool to Promote Alcohol and Drug Use Screening, Bri Intervention, and Referral to Treatment Skill Translation: A Mol App Development and Randomized Controlled Trial Protocol  Article Preparation Status/Stage *  At which stage in your article preparation are you currently (at the not submitted yet - in early draft status	ne time you	fill in this form	
A Digital Tool to Promote Alcohol and Drug Use Screening, Bri Intervention, and Referral to Treatment Skill Translation: A Mol App Development and Randomized Controlled Trial Protocol  Article Preparation Status/Stage *  At which stage in your article preparation are you currently (at the not submitted yet - in early draft status  not submitted yet - in late draft status, just before submissions.	ne time you	fill in this form	)
A Digital Tool to Promote Alcohol and Drug Use Screening, Bri Intervention, and Referral to Treatment Skill Translation: A Mol App Development and Randomized Controlled Trial Protocol  Article Preparation Status/Stage *  At which stage in your article preparation are you currently (at the not submitted yet - in early draft status  not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet	ne time you	fill in this form	)
A Digital Tool to Promote Alcohol and Drug Use Screening, Bri Intervention, and Referral to Treatment Skill Translation: A Mol App Development and Randomized Controlled Trial Protocol  Article Preparation Status/Stage *  At which stage in your article preparation are you currently (at the not submitted yet - in early draft status  not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet  submitted to a journal and after receiving initial reviewer con	ne time you	fill in this form	)
A Digital Tool to Promote Alcohol and Drug Use Screening, Bri Intervention, and Referral to Treatment Skill Translation: A Mol App Development and Randomized Controlled Trial Protocol  Article Preparation Status/Stage *  At which stage in your article preparation are you currently (at the not submitted yet - in early draft status  not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet  submitted to a journal and after receiving initial reviewer con submitted to a journal and accepted, but not published yet	ne time you	fill in this form	)
A Digital Tool to Promote Alcohol and Drug Use Screening, Bri Intervention, and Referral to Treatment Skill Translation: A Mol App Development and Randomized Controlled Trial Protocol  Article Preparation Status/Stage *  At which stage in your article preparation are you currently (at the not submitted yet - in early draft status) not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet submitted to a journal and after receiving initial reviewer consubmitted to a journal and accepted, but not published other:	ne time you	fill in this form	
A Digital Tool to Promote Alcohol and Drug Use Screening, Bri Intervention, and Referral to Treatment Skill Translation: A Mol App Development and Randomized Controlled Trial Protocol  Article Preparation Status/Stage *  At which stage in your article preparation are you currently (at the not submitted yet - in early draft status)  not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet  submitted to a journal and after receiving initial reviewer con submitted to a journal and accepted, but not published yet  published	ne time you mments		
A Digital Tool to Promote Alcohol and Drug Use Screening, Bri Intervention, and Referral to Treatment Skill Translation: A Mol App Development and Randomized Controlled Trial Protocol  Article Preparation Status/Stage *  At which stage in your article preparation are you currently (at the not submitted yet - in early draft status) not submitted yet - in late draft status, just before submission submitted to a journal but not reviewed yet  submitted to a journal and after receiving initial reviewer consubmitted to a journal and accepted, but not published yet published  Other:  Journal *  If you already know where you will submit this paper (or if it is a	ne time you mments		

CON	SORT-EHEALTH (V 1.6.1) - Submission/Publication Form Page 3 of 41
	Other:
v)	Manuscript tracking number *  If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)
	ono ms number (yet) / not (yet) submitted to / published in JMIR
	Other: JRP ms#7070
	TITLE AND ABSTRACT
	1a) TITLE: Identification as a randomized trial in the title
	1a) Does your paper address CONSORT item 1a? * I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")
	● yes
	Other:
	1a-i) Identify the mode of delivery in the title
	Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if Intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.
	1 2 3 4 5
	subitem not at all important $\bigcirc$ $\bigcirc$ $\bigcirc$ $\bigcirc$ essential
	Does your paper address subitem 1a-i? *
	Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for

your study

## CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Page 4 of 41

"Mobile App"	
1a-ii) Non-web-based compo Mention non-web-based compo telephone support").	onents or important co-interventions in title inents or important co-interventions in title, if any (e.g., "with
1	2 3 4 5
subitem not at all important	) O • O essential
11: " I to indicate direct quotes fr	bitem 1a-ii?  Ins from manuscript title (include quotes in quotation marks "like from your manuscript), or elaborate on this item by providing e ms, or briefly explain why the item is not applicable/relevant for
<b>1a-iii) Primary condition or t</b> Mention primary condition or to Example: A Web-based and Mc Diabetes: Randomized Control	arget group in the title, if any (e.g., "for children with Type I Diabetes") obile Intervention with Telephone Support for Children with Type I
1	1 2 3 4 5
subitem not at all important	o o essential
this" to indicate direct quotes t	abitem 1a-iii? * ons from manuscript title (include quotes in quotation marks "like from your manuscript), or elaborate on this item by providing he ms, or briefly explain why the item is not applicable/relevant for

The app was not developed with a specific population in mind.
1b) ABSTRACT: Structured summary of trial design,
methods, results, and conclusions
NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.
1b-i) Key features/functionalities/components of the intervention and comparator in the
METHODS section of the ABSTRACT
abstract. If possible, also mention theories and principles used for designing the site. Reep in mind
report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)
1 2 3 4 5
subitem not at all important O O O o essential
Does your paper address subitem 1b-i? *
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for
"The mobile app has three primary functions designed to increase
to be sized intent to deliver SRIPT: (1) review skills (ie. address
behavioral intent to deliver SBIRT: (1) review skills (ie, address knowledge and beliefs about SBIRT), (2) apply skills with patients (ie, build confidence and perceived behavioral control), and (3) report performance data (ie, increase accountability and social
knowledge and beliefs about SBIRT), (2) apply skills with patients
knowledge and beliefs about SBIRT), (2) apply skills with patients (ie, build confidence and perceived behavioral control), and (3) report performance data (ie, increase accountability and social
knowledge and beliefs about SBIRT), (2) apply skills with patients (ie, build confidence and perceived behavioral control), and (3) report performance data (ie, increase accountability and social norms and/or influence)."
knowledge and beliefs about SBIRT), (2) apply skills with patients (ie, build confidence and perceived behavioral control), and (3) report performance data (ie, increase accountability and social norms and/or influence)."  1b-ii) Level of human involvement in the METHODS section of the ABSTRACT Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved if any). (Note: Only report in the abstract what the main paper is reporting. If this
knowledge and beliefs about SBIRT), (2) apply skills with patients (ie, build confidence and perceived behavioral control), and (3) report performance data (ie, increase accountability and social norms and/or influence)."  1b-ii) Level of human involvement in the METHODS section of the ABSTRACT Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs.

## CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Page 6 of 41

Does your paper address subitem 1b-ii?  Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
"health and social service learners"
1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the
METHODS section of the ABSTRACT  Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)
subitem not at all important O O O o essential
Does your paper address subitem 1b-iii?
Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
"A randomized controlled trial (RCT) is in progress among health and social service learners (N=200) recruited from 3 universities and 6 different training programs in nursing, social work, internal medicine, psychiatry, and psychology."
1h-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5

### CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Page 7 of 41

subitem not at all important O O O essential
Does your paper address subitem 1b-iv?  Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
"Beta testing with advanced practice nursing students (N=22) indicated that the app and its associated assessment tools were acceptable and useful."
1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials  Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)  1 2 3 4 5  subitem not at all important O O O essential
Does your paper address subitem 1b-v?  Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study  "This report describes the process of TPB-based app development and testing, and the protocol for a RCT to determine the effectiveness of the app in enhancing skill translation. If effective, this approach could improve SBIRT implementation, fidelity, and clinical outcomes."

#### INTRODUCTION

2a) In INTRODUCTION: Scientific background and explanation of rationale

2a-i) Problem and the type of system/solution

### CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Page 8 of 41

Describe the problem and the type of system/solution that is object of the study: intended as standalone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)

1 2 3 4 5 subitem not at all important  $\bigcirc$   $\bigcirc$   $\bigcirc$   $\bigcirc$  essential

#### Does your paper address subitem 2a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The transition from learning clinical skills to sustained changes in health provider behavior is a known problem. Even when evidence-based treatments are available and implementation decisions have been made, workforce development and sustained intervention delivery present formidable challenges [1]. For example, maintaining fidelity to evidence-based treatments (eg, cognitive behavioral therapy [2]), often requires strategies to support ongoing learning such as supervision and coaching [3].

#### 2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

1 2 3 4 5 subitem not at all important  $\bigcirc$   $\bigcirc$   $\bigcirc$   $\bigcirc$  essential

#### Does your paper address subitem 2a-ii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Screening, brief intervention, and referral to treatment (SBIRT) for unhealthy alcohol and drug use is an important example of a widely-trained skill that has fallen short in translation [6]. SBIRT is designed to reach individuals in health or social service settings who use substances at a range of levels, including those who may not yet meet criteria for alcohol or drug use disorders. Components include screening for hazardous drinking and drug use and related problems, delivering brief motivational

2b) In INTRODUCTION: Specific objectives or hypotheses

### CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form Page 9 of 41

Does your paper address CONSORT subitem 2b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The aim of this paper is to describe the process of TPB-based mobile alcohol and drug SBIRT app development, beta testing, and protocol for a randomized controlled trial (RCT) comparing health professional learners with access to the app (intervention arm) to learners without access to the app (control arm). We hypothesize that participants in the intervention arm will be more likely to deliver SBIRT in clinical placements than those in the control arm and will be more likely to report intention to deliver

#### **METHODS**

### 3a) Description of trial design (such as parallel, factorial) including allocation ratio

Does your paper address CONSORT subitem 3a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The study is a RCT of an SBIRT mobile app to facilitate skill translation from classroom to clinical placements among 200 graduate and post-graduate learners (Figure 2). Following SBIRT instruction, participants are enrolled and randomized to the experimental (use of the app) or control (no access to the app) condition. All participants complete self-report measures over the study duration (10 weeks)."

#### 3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

Does your paper address CONSORT subitem 3b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional

information not in the ms, or briefly explain why the item is not applicable/relevant for your study n/a

# CONSORT-EHEALTH (V 1.6.1) - Submission/Publication F... Page 10 of 41

3b-i)	Bug	fixes,	Downtimes,	Content	Changes
-------	-----	--------	------------	---------	---------

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

2 subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Once the final beta version of the app was developed, our team chose a small cohort of nurse practitioner learners (N=22) at the University of San Francisco to beta test the app for 3 months. Our testers included learners in an advanced practice nursing training program who were enrolled in a clinic placement. The team tested and refined the app prior to starting the controlled trial. Beta testing results are described below."

### 4a) Eligibility criteria for participants

#### Does your paper address CONSORT subitem 4a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants must have had prior classroom or online training in SBIRT within the past year and may not have previously used an SBIRT app. For learners who have not yet completed classroombased SBIRT instruction, they are required to complete the following 3 online training modules developed by the research team: (1) Introduction to SBIRT, (2) Screening, and (3) Brief Intervention."

#### 4a-i) Computer / Internet literacy

Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.

> 5 3 4 2

subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

Does your paper address subitem 4a-i?

## CONSORT-EHEALTH (V 1.6.1) - Submission/Publication F... Page 11 of 41

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "The learner must be enrolled in a field placement and is required to have a mobile device to be in the study (Android or iOS)."
4a-ii) Open vs. closed, web-based vs. face-to-face assessments:  Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.
1 2 3 4 5
subitem not at all important \( \cap \cap \cap \cap \cap \cap \cap \cap
Does your paper address subitem 4a-ii? *  Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "Project faculty identified SBIRT educators at the participating training programs and received permission to recruit students.  Absent learners are invited to participate via email recruitment.  Participants provide informed consent to participate either live in classroom settings or via email."
4a-iii) Information giving during recruitment Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.  1 2 3 4 5
subitem not at all important O O O essential
Does your paper address subitem 4a-iii?

### CONSORT-EHEALTH (V 1.6.1) - Submission/Publication F... Page 12 of 41

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Students are recruited during scheduled classroom time using a detailed information sheet that specifies expectations, timing, and types of data to be collected."

# 4b) Settings and locations where the data were collected

Does your paper address CONSORT subitem 4b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The trial is being carried out at 3 sites, among 6 training programs: San Francisco State University (Social Work and Nursing), University of California, San Francisco (Internal Medicine and Psychiatry), and University of San Francisco (Nursing and Psychology). Institutional review boards at the 3 sites approved all study procedures."

#### 4b-i) Report if outcomes were (self-)assessed through online questionnaires

Clearly report if outcomes were (self-)assessed through online questionnaires (as common in webbased trials) or otherwise.

1 2 3 4 5

subitem not at all important  $\bigcirc$   $\bigcirc$   $\bigcirc$   $\bigcirc$  essential

#### Does your paper address subitem 4b-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"At baseline, all participants answer a TPB-based questionnaire via Qualtrics (control) or directly on the app (intervention). At the end of each week, all participants are asked to respond to a brief Qualtrics survey about how often they used SBIRT either by text message (short message service, SMS) or by email. Upon completion of their clinical rotation, all learners are asked to repeat the original TPB-based questionnaire and to provide general feedback about either the app usage (intervention) or

4b-ii) Report how institutional affiliations are displayed

# CONSORT-EHEALTH (V 1.6.1) - Submission/Publication F... Page 13 of 41

eport how institutional a ffiliations with prestigiou ith regards to an interve	ntion.(Not	a requ	ii eu i	item (	describe	only if t	nis iii	ay Dias	results	)
	1 2	2 3	4	5						
ubitem not at all importa	int () (	0 0	0	) es	sential					
Ditem not at an importe	0									
oes your paper addrest topy and paste relevant to indicate direct quotes information not in the ma	sections f from your s, or briefly	rom the manus explair	e mai cript n wh	), or ela y the ite	em is not	applica	CHILIN	DIOAIG	BILLY CACECO	1010011001
Affiliations were describ carried out at 3 sites, at State University (Social California, San Francis University of San Francis	mong 6 tra Work and co (Interna	aining p d Nursir al Medic	rogra ng), l cine :	ams: Sa Univers and Psy	an Franc ity of ychiatry)	1500				
details to allo they were act	w rep ually	olica adm	tio nin	n, in iste	iclud red	ing l	10V	v an	d wr	nen
details to allo they were act 5-i) Mention names, c Mention names, credent authors/evaluators are	w repaired in the company of the com	olica adm , affilia tions of develop	tion the oper o	ister	red  e developers, spo oftware,	ppers, sonsors, a	nov pons	ors, an	d who	ers
details to allothey were act  5-i) Mention names, c  Mention names, credent authors/evaluators are	w repaired in the company of the com	olica adm , affilia tions of develop	tion the oper o	ister	red  e developers, spo oftware,	ppers, sonsors, a	nov pons	ors, an	d who	ers
details to allo they were act 5-i) Mention names, c Mention names, credent authors/evaluators are of of interest" section or m	redential cial, affiliat owners or entioned	adm , affilia ions of develop elsewho	tion the oper opere in	isters of the develop of the so	red  e developers, spo oftware,	ppers, s nsors, a this nee t).	nov pons	ors, an	d who	ers
they were act  5-i) Mention names, c  Mention names, credent authors/evaluators are of interest" section or m  subitem not at all impor	redential idal, affiliat owners or entioned	adm , affilia ions of develop elsewho	tionin tion the coper of the co	s of the develop of the son the man	red e developers, spo oftware, sanuscrip	ppers, s nsors, a this nee t).	pons nd ow ds to	ors, an ors, an ores [6 be decl	d who	ers a "Confli
details to allothey were act  5-i) Mention names, commention names, credent authors/evaluators are confinterest" section or most subitem not at all important to indicate direct quote information not in the notated to a local content of the nota	redential tial, affiliat towners or tentioned  tant  ess subit t sections s from you ns, or brief	adm , affilia ions of develop elsewher 2 3  em 5-i from the ur manu fly explain	tion the oper of the manner of	s of the develop of the son the man	e developers, spooftware, anuscripe essential	ppers, sonsors, athis need t).	pons and ow ds to	ors, and ors	d who	ers a "Confli
	redential tial, affiliat owners or tentioned  tant  tess subit t sections s from you ns, or brief c app developes	adm , affilia ions of developelsewher 2 3 cem 5-i from their manual fly explain elopers their pri	tion the oper of ere in a scrip and muscrip and muscrip and with the control of t	s of the develop of the son the man sori pt), or early the inverse sori were so	e developers, sponoftware, anuscripe essential	ppers, sonsors, athis need t).	pons and ow ds to	ors, and ors	d who	ers a "Confli
they were act  5-i) Mention names, c  Mention names, credent authors/evaluators are of interest" section or m  subitem not at all import  Does your paper addr Copy and paste relevant o indicate direct quote information not in the n  "Open Health Network development partner."	redential tial, affiliat owners or tentioned  tant  tess subit t sections s from you ns, or brief c app developes	adm , affilia ions of developelsewher 2 3 cem 5-i from their manual fly explain elopers their pri	tion the oper of ere in a scrip and muscrip and muscrip and with the control of t	s of the develop of the son the man sori pt), or early the inverse sori were so	e developers, sponoftware, anuscripe essential	ppers, sonsors, athis need t).	pons and ow ds to	ors, and ors	d who	ers a "Confli

https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc\_Oi... 4/12/2017

5-ii) Describe the history/development process

# CONSORT-EHEALTH (V 1.6.1) - Submission/Publication F... Page 14 of 41

Describe the history/development process of the app (e.g., focus groups, usability testing), as these will ha with interpreting results.	olication and previous formative evaluations ve an impact on adoption/use rates and help
1 2 3 4 5	
subitem not at all important OOOOO	essential
Does your paper address subitem 5-ii?	the state of the "like this"
Copy and paste relevant sections from the manuscr to indicate direct quotes from your manuscript), or e information not in the ms, or briefly explain why the	I STOLES IN THIS HELL DAY DIVING A A A
"App Development An interprofessional team worked to develop the T The team was comprised of faculty members with expertise in SBIRT training and implementation an clinical psychologists with doctorate degrees, an ir physician, an advanced practice nurse with a doct and an experienced project manager. Existing mo identified to determine needs in the field and to lea	PB-based app. prior research ad included two atternal medicine orate degree, bile apps were arn about
5-iii) Revisions and updating	od (or version number of the
Revisions and updating. Clearly mention the date are application/intervention (and comparator, if application intervention underwent major changes during the erand/or content was "frozen" during the trial. Described changing content which may have an impact on the events see item 3b).	valuation process, or whether the development
1 2 3 4 5	
subitem not at all important OOOO	essential
Does your paper address subitem 5-iii?  Copy and paste relevant sections from the manuscript to indicate direct quotes from your manuscript), or information not in the ms, or briefly explain why the	e item is not applicable/relevant for your study
"Once the final beta version of the app was developed a small cohort of nurse practitioner learner University of San Francisco to beta test the app of testers included learners in an advanced practice program who were enrolled in a clinic placement completed the questionnaires and processes to larger RCT. Full TPB-based surveys (see "Pre/P Questions") were repeated at the end of the beta	oped, our team rs (N=22) at the for 3 months. Our re nursing training Learners re used in the rost Assessment
5-iv) Quality assurance methods	^
Provide information on quality assurance methods provided [1], if applicable.	s to ensure accuracy and quality of information

1 2 3 4 5

subitem not at all important ( ) ( ) ( ) essential
Does your paper address subitem 5-iv?  Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "The wireframes were given to the developers, who provided an initial alpha version. Team members tested the alpha version individually and worked with the developers to continue refining the flow and content for subsequent beta testing."
5-v) Ensure replicability by publishing the source code, and/or providing
screenshots/screen-capture video, and/or providing flowcharts of the algorithms used Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.
1 2 3 4 5
subitem not at all important ( ) ( ) ( ) essential
Does your paper address subitem 5-v?  Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study  Screen shots are included in the manuscript, along with a reference and link to the mobile app itself, which is freely available online.
5-vi) Digital preservation
Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, <a href="webcitation.org">webcitation.org</a> , and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.
1 2 3 4 5
subitem not at all important \( \cap \) \( \cap \) essential

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication F... Page 15 of 41

# CONSORT-EHEALTH (V 1.6.1) - Submission/Publication F... Page 16 of 41

Does your	paper	address	subitem	5-vi?
-----------	-------	---------	---------	-------

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

See Reference #55: "Maurer D. Review of UCSF OHN SBIRT app, evidence based intervention for substance abuse. iMedicalApps; 2016. http://www.imedicalapps.com/2016/08/ucsfohn-sbirt-app-evidence-based-intervention-substance-abuse/#. Archived at: http://www.webcitation.org/6lpQxrAQd."

#### 5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

1 2 3 4 5 subitem not at all important O O O essential

#### Does your paper address subitem 5-vii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants in the intervention group are asked to download the app, use it in their clinical rotations (either on their personal mobile phones or tablets)." It was provided free of charge.

#### 5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and - if computer-mediated communication is a component - whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

1 2 3 4 5 subitem not at all important O O O o essential

# CONSORT-EHEALTH (V 1.6.1) - Submission/Publication F... Page 17 of 41

Popy and paste relevant sections from the manuscript (include quotes in quotation marks "like this o indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "On the level of individual provider (or learner) behavior, the theory of planned behavior (TPB) provides a well-validated, conceptual model that identifies both internal and external key factors that could influence SBIRT skill translation [40]. In the TPB model, behavioral intent (to perform the behavior of interest) is determined by attitudes and/or beliefs about the behavior, perceived social norms, and perceived behavioral control. The TPB is contextualized for SBIRT skill translation in Figure 1."  5-ix) Describe use parameters  Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.  1 2 3 4 5  subitem not at all important  essential  Does your paper address subitem 5-ix?  Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study. This was determined by participants in the intervention group.	oes your paper address subitem 5-viii? *	1 811 01:08
"On the level of individual provider (or learner) behavior, the theory of planned behavior (TPB) provides a well-validated, conceptual model that identifies both internal and external key factors that could influence SBIRT skill translation [40]. In the TPB model, behavioral intent (to perform the behavior of interest) is determined by attitudes and/or beliefs about the behavior, perceived social norms, and perceived behavioral control. The TPB is contextualized for SBIRT skill translation in Figure 1."  5-ix) Describe use parameters  Describe use parameters  Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.  1 2 3 4 5  subitem not at all important  essential  Does your paper address subitem 5-ix?  Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study		
Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.  1 2 3 4 5  subitem not at all important	"On the level of individual provider (or learner) behavior, the theory of planned behavior (TPB) provides a well-validated, conceptual model that identifies both internal and external key factors that could influence SBIRT skill translation [40]. In the TPB model, behavioral intent (to perform the behavior of interest) is determined by attitudes and/or beliefs about the behavior, perceived social norms, and perceived behavioral control. The	
Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.  1 2 3 4 5  subitem not at all important	E iv) Deceribe use parameters	
Does your paper address subitem 5-ix?  Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study	Describe use parameters (e.g., intended "doses" and optimal timing instructions or recommendations were given to the user, e.g., regard	for use). Clarify what ling timing, frequency,
Does your paper address subitem 5-ix?  Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like thi to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study	1 2 3 4 5	
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like thi to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study	subitem not at all important ( ) ( ) ( ) essential	
	Copy and paste relevant sections from the manuscript (include quo	SILEITIDA DIOMININA aggriciona
THE CHARGE THE LOVE OF THE THE STREET STREET	5-x) Clarify the level of human involvement	

Does your paper address subitem 5-x?

subitem not at all important  $\bigcirc$   $\bigcirc$   $\bigcirc$   $\bigcirc$  essential

## CONSORT-EHEALTH (V 1.6.1) - Submission/Publication F... Page 18 of 41

Copy and paste relevant secti to indicate direct quotes from information not in the ms, or l "Participants in the intervent app, use it in their clinical ro mobile phones or tablets), a via a Qualtrics link."	briefl	y ex group	plain plain p are	why ask	the i	item is not applic download the personal	s in quotation marks "like this" tem by providing additional able/relevant for your study
5-xi) Report any prompts/	remi	nde	rs us	sed			
Report any prompts/reminde	ers us what	sed: trig	Clari gere	fy if the	em, II ed fo	equency etc. it in or the trial, and the	e level of prompts/reminders
	1	2	3	4	5		
subitem not at all important	0	0	0	0	0	essential	
. It is I'm at a contag from	m your bries and rectly cipar v often services and control of the services and control	ur m fly e swer y on its a en th ce, s ion, ques	anus xplai a Ti the a re as ey u SMS; all le	PB-b app ( sked sed ( ) or b earned	ased interiore SBIR by emers are and e (interior)	elaborate on this attem is not applied questionnaire evention). At the spond to a brief it either by texturail. Upon e asked to to provide	es in quotation marks "like this" item by providing additional cable/relevant for your study
5-xii) Describe any co-int	erve	ntio	ns (	incl.	trair	ning/support)	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Describe any co-intervention provided in addition to the to designed as stand-alone into necessary to distinguish be for a routine application out	arget ervei twee	ted entior	Hea The lev	Ith In is inc el of	iterve clude train	ention, as eriealur s training sessior ing required for th	ns and support [1]. It may be ne trial, and the level of training
	1	2	3	4	5		
subitem not at all important	t ()	0	0		0	essential	
Does your paper address Copy and paste relevant se	otion	c fre	ana th	ne m	anus	cript (include quo	otes in quotation marks "like this" s item by providing additional licable/relevant for your study

information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Participants must have had prior classroom or online training in SBIRT within the past year and may not have previously used an SBIRT app. For learners who have not yet completed classroom-based SBIRT instruction, they are required to complete the following 3 online training modules developed by the research team: (1) Introduction to SBIRT, (2) Screening, and (3) Brief Intervention."

# 6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

#### Does your paper address CONSORT subitem 6a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Likert-scaled items assess attitudes and beliefs including importance and efficacy of SBIRT, perceived patient willingness to participate in SBIRT, substance use epidemiology and clinical significance, and subjective norms and perceived behavioral control in the clinic setting. Three items assess confidence in the respondents' ability to screen for alcohol or drug use problems, deliver a brief intervention, and to make referrals. All participants complete this questionnaire at baseline and again at 10 weeks."

# 6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed

If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].

1 2 3 4 5

subitem not at all important OOOO essential

#### Does your paper address subitem 6a-i?

Copy and paste relevant sections from manuscript text

Questionnaires were not validated for online use.

6a-ii) Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored

### CONSORT-EHEALTH (V 1.6.1) - Submission/Publication F... Page 20 of 41

Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.

1 2 3 4 5 subitem not at all important  $\bigcirc$   $\bigcirc$   $\bigcirc$   $\bigcirc$  essential

#### Does your paper address subitem 6a-ii?

Copy and paste relevant sections from manuscript text

"At the end of each clinic week, every participant is sent (via email or text) a Qualtrics link asking them to report the total number of patients they have seen in the preceding week. Participants then are asked how many of those patients they screened for alcohol, drug, or tobacco use, how many they did a brief intervention with, and how many they either referred to a specialty substance use treatment clinic or discussed with their field supervisor."

# 6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained

Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).

1 2 3 4 5

subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 6a-iii?

Copy and paste relevant sections from manuscript text

"Learners completed the questionnaires and processes to be used in the larger RCT. Full TPB-based surveys (see "Pre/Post Assessment Questions") were repeated at the end of the betatesting period, followed by a debrief focus group."

# 6b) Any changes to trial outcomes after the trial commenced, with reasons

#### Does your paper address CONSORT subitem 6b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication F	Page 21 of 4
--	--------------

None	
7a) How sample size was determined the NPT: When applicable, details of whether and how the was addressed	rmined ne clustering by care provides or center
7a-i) Describe whether and how expected attrition was calculating the sample size  Describe whether and how expected attrition was taken is size.	
1 2 3 4 5	
subitem not at all important \( \cap \) \( \cap \) \( \cap \) esse	ential
Does your paper address subitem 7a-i?  Copy and paste relevant sections from manuscript title (this" to indicate direct quotes from your manuscript), or additional information not in the ms, or briefly explain whyour study	elaborate on this item by providing
n/a	

# 7b) When applicable, explanation of any interim analyses and stopping guidelines

Does your paper address CONSORT subitem 7b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

# 8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

#### Does your paper address CONSORT subitem 8a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"A Web-based randomization tool is used to generate group assignments. Randomization is stratified by training program in order to have an even distribution of learners in the intervention and control groups from each program."

# 8b) Type of randomisation; details of any restriction (such as blocking and block size)

#### Does your paper address CONSORT subitem 8b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Standard randomization procedures used in behavioral intervention studies are followed [45] using a variable block size with a 1:1 allocation to the intervention or control arm design."

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

# CONSORT-EHEALTH (V 1.6.1) - Submission/Publication F... Page 23 of 41

С	copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "Learners are assigned an identification number that is used for the randomization."
1	10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions
	Does your paper address CONSORT subitem 10? *  Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study "These procedures are carried out by the study project manager."
	11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how NPT: Whether or not administering co-interventions were blinded to group assignment
	11a-i) Specify who was blinded, and who wasn't Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).
	1 2 3 4 5
	subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential
	Does your paper address subitem 11a-i? *

# CONSORT-EHEALTH (V 1.6.1) - Submission/Publication F... Page 24 of 41

Copy and paste releva to indicate direct quot information not in the			clude quotes in quotat ate on this item by pro s not applicable/releva	
Participants were no				
11a-ii) Discuss e.g.	, whether particip	oants knew which	ch intervention was t	he "intervention of
interest" and which		higgson of	nd certain expectations	s - discuss e.g.,
Informed consent pro	knew which interv	ention was the "ir	tervention of interest"	and which one was
the "comparator".				
	1 2	3 4 5		
subitem not at all imp	portant O O (	O O esse	ntiai	
Does your paper ad	Idress subitem 1	1a-ii?		
and the contractions	est anotions from	the manuscript (i	include quotes in quote	ation marks "like this"
	and the second second	amagript) or along	APOTO OD TRUS HEILI DV DI	Oviding additional
information not in the	e ms, or briefly exp	nain why the item	is not applicable, lete	rant for your order
Given the study det the intervention of i	sign, it was not poi interest (app vs. no	ssible to blind par b use of app).	ticipants to	
the intervention of				

# 11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

#### Does your paper address CONSORT subitem 11b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

n/a			
			a.
2a) Stati	istical methods (	used to comp	pare groups for
orimary a	nd secondary ou	ıtcomes	
IPT: When appleenters was add	licable, details of whether ar dressed	nd how the clustering	by care providers or
oes your pape	r address CONSORT subite	m 12a? *	The state of the s
Copy and paste r	elevant sections from the mar quotes from your manuscript n the ms, or briefly explain why	nuscript (include quotes ) or elaborate on this ite	elli by providing additional
"Chi-square tes (ANOVA) tests regression mod delivery in the t (eq. beliefs abo	sts, student t tests, and analysic will be used to determine includeds. Bivariate analyses will exit two arms and comparison of Tout SBIRT, social norms and in avioral control)."	is of variance usion in multivariate amine rate of SBIRT PB-based measures	
Imputation technintervention/conparticipants who statistical analys	ion techniques to deal with a niques to deal with attrition / n nparator as intended and attrit o did not use the application or sis (a complete case analysis	nissing values: Not all p tion is typically high in e r dropped out from the t is strongly discouraged,	health trials. Specify how rial were treated in the
techniques sucr	as LOCF may also be problen		
subitem not at a	all important () () ()	<ul><li>essential</li></ul>	
subitem not at a	all important () () ()	essential	
Door your name	or address subitem 12a-i?	k	The Wiles the
Does your pap Copy and paste	er address subitem 12a-i? *	anuscript (include quote	Telli Dy Di Oviding additional
Does your pap Copy and paste	er address subitem 12a-i?	anuscript (include quote	Telli Dy Di Oviding additional
Does your pap Copy and paste to indicate direc information not	er address subitem 12a-i? *	anuscript (include quote	Telli Dy Di Oviding additional
Does your pap Copy and paste to indicate direc information not	er address subitem 12a-i? *	anuscript (include quote	Telli Dy Di Oviding additional
Does your pap Copy and paste to indicate direc information not	er address subitem 12a-i? *	anuscript (include quote	Telli Dy Di Oviding additional

# 12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

Does	vour	paper	address	CONSORT	subitem	12b?	*
------	------	-------	---------	---------	---------	------	---

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Multivariate analyses (logistic and multiple regression) will examine the impact of these factors on SBIRT delivery."

# X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

X26-i) Comment on ethics committee approval

1 2 3 4 5

subitem not at all important ( ) ( ) ( ) essential

#### Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The trial is being carried out at 3 sites, among 6 training programs: San Francisco State University (Social Work and Nursing), University of California, San Francisco (Internal Medicine and Psychiatry), and University of San Francisco (Nursing and Psychology). Institutional review boards at the 3 sites approved all study procedures."

#### x26-ii) Outline informed consent procedures

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.

1 2 3 4 5

subitem not at all important  $\bigcirc$   $\bigcirc$   $\bigcirc$   $\bigcirc$  essential

## CONSORT-EHEALTH (V 1.6.1) - Submission/Publication F... Page 27 of 41

Does your	paper	address	subitem	X26-ii?
-----------	-------	---------	---------	---------

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Students are recruited during scheduled classroom time using a detailed information sheet that specifies expectations, timing, and types of data to be collected. Absent learners are invited to participate via email recruitment. Participants provide informed consent to participate either live in classroom settings or via email."

#### X26-iii) Safety and security procedures

Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)

1 2 3 4 5

subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Study participants (trainees, N=200) are adult health professional learners in one of the designated training programs."

"The learner must be enrolled in a field placement."

#### RESULTS

# 13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

#### Does your paper address CONSORT subitem 13a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

CONSORT-EHEALTH (V 1.6.1) - Submissio	n/Publication F	Page 28	of 41

Recruitment is still in process.	
101 ) 5	l ovelusions after
13b) For each group, losses and	Lexicusions arter
andomisation, together with re-	asons
	orr D. C blu this is shown in 2
Ooes your paper address CONSORT subitem 13b? (N	OTE: Preferably, this is shown in a
CONSORT flow diagram) * Copy and paste relevant sections from the manuscript (inc	clude quotes in quotation marks "like this"
a indicate direct quotes from your manuscript), or elabora	ite on this item by providing additions.
of indicate direct quotes from your manager, or or briefly explain why the item is	s not applicable/relevant for your study
Recruitment is still in process.	
13b-i) Attrition diagram	
Strongly recommended: An attrition diagram (e.g., proport the intervention/comparator in each group plotted over tir	tion of participants still logging in or using me, similar to a survival curve) or other
the intervention/comparator in each group plotted over the figures or tables demonstrating usage/dose/engagement	i.
1 2 3 4 5	
subitem not at all important 🔘 🔘 🔘 🔘 essen	rtial
Does your paper address subitem 13b-i?	
or and mosts relevant sections from the manuscript of	cite the figure number if applicable
(: lude quates in quotation marks "like this" to indicate (	illect dnotes nour your manascribe, or
elaborate on this item by providing additional information item is not applicable/relevant for your study	Thot in the ms, or briefly explain my are
Recruitment is still in process.	
Neordiament to date any process	

# 14a) Dates defining the periods of recruitment and follow-up

Does your paper address CONSORT subitem 14a? *  Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this to indicate direct quotes from your manuscript), or elaborate on this item by providing additional to indicate direct quotes from your manuscript).	s"
to indicate direct quotes from your manuscript), or elaborate of this technology information not in the ms, or briefly explain why the item is not applicable/relevant for your study	
Recruitment is still in process.	
14a-i) Indicate if critical "secular events" fell into the study period Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery resources"	
1 2 3 4 5	
subitem not at all important ( ) ( ) ( ) essential	
Does your paper address subitem 14a-i?	aio"
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like the to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study	
n/a	

# 14b) Why the trial ended or was stopped (early)

Does your paper address CONSORT subitem 14b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

15) A table showing baseli	ne demographic and
clinical characteristics for	each group
NPT: When applicable, a description of care p	providers (case volume, qualification, expertise
etc.) and centers (volume) in each group	
Does your paper address CONSORT subitem	1 15? *
	recript (include quotes in quotation marks) like this
to indicate direct quotes from your manuscript), information not in the ms, or briefly explain why	or elaborate on this item by providing additional the item is not applicable/relevant for your study
Recruitment is still in process.	
	¥
15-i) Report demographics associated with	digital divide issues
	port demographics associated with digital divide economic status, computer/Internet/ehealth literacy
of the participants, if known.	Conornia status, comp
1 2 3 4	5
subitem not at all important OOOO	() essential

information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Recruitment is still in process.

# 16) For each group, number of participants (denominator) included in each analysis and whether

# the analysis was by original assigned groups

16-i) Report multiple "denominators" and provide definitions Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define "use" of the intervention. subitem not at all important O O O essential Does your paper address subitem 16-i? \* Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study This will be reported once the trial is concluded. 16-ii) Primary analysis should be intent-to-treat Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-i). subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential Does your paper address subitem 16-ii? Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study Planned analyses are consistent with "intent-to-treat" based on assignment to study conditions.

# 17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

Does your paper address CONSORT subitem 17a? \*
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
This will be reported once the trial is concluded.

17a-i) Presentation of process outcomes such as metrics of use and intensity of use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

1 2 3 4 5

subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This will be reported once the trial is concluded.

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

Does your paper address CONSORT subitem 17b? \*

### CONSORT-EHEALTH (V 1.6.1) - Submission/Publication F... Page 33 of 41

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study  This will be reported once the trial is concluded.
18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory
Does your paper address CONSORT subitem 18? *  Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study  This will be reported once the trial is concluded.
18-i) Subgroup analysis of comparing only users  A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).
subitem not at all important ( ) ( ) ( ) essential
Does your paper address subitem 18-i?  Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study n/a

# 19) All important harms or unintended effects in each group

g. oup
(for specific guidance see CONSORT for harms)
Does your paper address CONSORT subitem 19? *
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this
to indicate direct quotes from your manuscript), or elaborate on this item by providing additional
information not in the ms, or briefly explain why the item is not applicable/relevant for your study
This will be reported once the trial is concluded.
19-i) Include privacy breaches, technical problems
Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems,
and other unexpected/unintended incidents. "Unintended effects" also includes unintended positiv
effects [2].
1 2 3 4 5
subitem not at all important O O O O essential
Does your paper address subitem 19-i?
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this
to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study
This will be reported once the trial is concluded.
This will be reported office the that to continued.
19-ii) Include qualitative feedback from participants or observations from
staff/researchers
William Committee of the Committee of th

Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

Does your paper address subitem 19-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Debrief participants reported satisfaction with the Apply and Review sections, which included brief intervention scripts, video demonstrations, the level of detail included in the "Referral to Treatment" section, and inclusion of the PHQ-9 (because this is often required in clinic settings to screen for depression). Suggestions for improvement focused on ease of sign-on and reducing the need for navigation (eg, by having multiple scale items appear on a single screen). These formative beta test data

#### DISCUSSION

# 22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)

Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).

1 2 3 4 5

subitem not at all important \( \cap \) \( \cap \) \( \cap \) essential

#### Does your paper address subitem 22-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The study team found that the TBP model was a useful framework for SBIRT mobile app development and that beta testers responded positively overall to the content and features of the app. The app was developed as a tool to promote translation of substance use screening and intervention skills from classroom to clinical settings. Our intent was to assist in workforce development and promote the broader use of evidence-based interventions to reduce alcohol and drug problems among

22-ii) Highlight unanswered new questions, suggest future research

Highlight unanswered new questions, suggest future research.

1 2 3 4 5

Copy and paste relevant to indicate direct quotes information not in the m	from your manuscript), or elabora s, or briefly explain why the item is	clude quotes in quotation marks "like this" ate on this item by providing additional s not applicable/relevant for your study
This will be described	once trial results are reported.	
,	ations, addressing sion, and, if relevar	sources of potential nt, multiplicity of
often look at a multiplic	ealth trials: Participants in ehealth ty of outcomes, increasing risk for	trials are rarely blinded. Ehealth trials a Type I error. Discuss biases due to
non-use of the intervent unexpected events.	on/usability issues, biases throug	n informed consent procedures,
mexpected events.		
mexpected events.	1 2 3 4 5	
		ial
		ial
subitem not at all impor	ant O O O essent	ial
subitem not at all impor  Does your paper addre  Copy and paste relevant to indicate direct quotes	ess subitem 20-i? * sections from the manuscript (inc	clude quotes in quotation marks "like this ate on this item by providing additional
Does your paper address Copy and paste relevant to indicate direct quotes information not in the machine to the RCT is conducted schools in nursing, psymay not generalize to	ess subitem 20-i? * sections from the manuscript (inc	clude quotes in quotation marks "like this ate on this item by providing additional s not applicable/relevant for your study g in the e, and g or to
Does your paper address your paper address to indicate direct quotes information not in the machine to reconstruct the schools in nursing, psymay not generalize to	ess subitem 20-i? * sections from the manuscript (income your manuscript), or elaborate, or briefly explain why the item is d in the context of graduate training chology, social work, and medicinother types of professional training	clude quotes in quotation marks "like this ate on this item by providing additional s not applicable/relevant for your study g in the e, and g or to

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication F... Page 36 of 41

21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

#### CONSORT-EHEALTH (V 1.6.1) - Submission/Publication F... Page 37 of 41

21-i) Generalizabilit	y to other	populations
-----------------------	------------	-------------

Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations

1 2 3 4 5
subitem not at all important O O O essential

#### Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"Some clinical settings and supervisors may not be support the use of SBIRT, and this could impact a learner's ability to use the app. Although use of mobile devices is becoming widespread, limitations in access to technology could impact the reach of this tool [36,56]. The app was not designed to integrate responses to screening measures to electronic health records, which could limit its applicability in some clinical settings."

### 21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

1 2 3 4 5
subitem not at all important O O O essential

#### Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"A limitation of the trial methodology that could impact our study results is the inclusion of incentives within the intervention arm for participants to use the app, which likely would not exist in actual clinical settings."

#### OTHER INFORMATION

#### 23) Registration number and name of trial registry

#### Does your paper address CONSORT subitem 23? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"The study is not registered with ClinicalTrials.gov because the design does not include a collection of clinical data or patient-level outcomes."

# 24) Where the full trial protocol can be accessed, if available

#### Does your paper address CONSORT subitem 24? \*

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

n/a

# 25) Sources of funding and other support (such as supply of drugs), role of funders

#### Does your paper address CONSORT subitem 25? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

"This study was supported by a grant from the Substance Abuse and Mental Health Services Administration (U79TI025404)."

#### X27) Conflicts of Interest (not a CONSORT item)

X27-i) State the relation In addition to the usual de									if the
study team towards the sy from or identical with the	ystem l develor	peing pers/	eva spor	luate isors	d, i.e s of t	e., state if the he interventio	authors/ on.	evaluators are distinct	
	1	2	3	4	5				
subitem not at all importa	nt O	0	0	0	0	essential			
Does your paper addres	s subi	tem	X27	-i?					
Copy and paste relevant s to indicate direct quotes f information not in the ms,	rom yo	ur m	anus	cript	), or	elaborate on	this item	by providing addition	al
None									
About the CO	VS0	RT	E	HE	AL	TH che	ecklis	st	
About the CON									
As a result of using this  yes, major changes  yes, minor changes									
As a result of using this  yes, major changes									
As a result of using this  yes, major changes  yes, minor changes	s check	dist,	did	you	mak	ce changes in	n your m	nanuscript? *	
As a result of using this  yes, major changes  yes, minor changes  no	s check	dist,	did	you	mak	ce changes in	n your m	nanuscript? *	
As a result of using this  yes, major changes  yes, minor changes  no	s check	dist,	did	you	mak	ce changes in	n your m	nanuscript? *	
As a result of using this  yes, major changes  yes, minor changes  no	s check	dist,	did	you	mak	ce changes in	n your m	nanuscript? *	
As a result of using this  yes, major changes  yes, minor changes  no	s check	dist,	did	you	mak	ce changes in	n your m	nanuscript? *	

As a result of using	this checklist, do you thin	ık your manuscript has imp	proved? *
<ul><li>yes</li></ul>			
O no			
Other:			
O other.			
Would you like to be	come involved in the CON		on and writing an
Would you like to be This would involve for 'Explanation and Elab	example becoming involved	NSORT EHEALTH group? d in participating in a worksho	op and writing an
Would you like to be This would involve for "Explanation and Elab  yes  no	example becoming involved		op and writing an
Would you like to be This would involve for 'Explanation and Elab	example becoming involved		op and writing an
Would you like to be This would involve for 'Explanation and Elab  yes  no Other:	example becoming involved	d in participating in a worksho	op and writing an
Would you like to be This would involve for 'Explanation and Elab  yes  no Other:	example becoming involved pration" document	d in participating in a worksho	op and writing an
Would you like to be This would involve for "Explanation and Elab  yes  no Other:	example becoming involved pration" document	d in participating in a worksho	op and writing an
Would you like to be This would involve for "Explanation and Elab  yes  no Other:	example becoming involved pration" document	d in participating in a worksho	op and writing an
Would you like to be This would involve for "Explanation and Elab  yes  no Other:	example becoming involved pration" document	d in participating in a worksho	op and writing an

page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

#### Final step: Click submit!

Click submit so we have your answers in our database!

#### CONSORT-EHEALTH (V 1.6.1) - Submission/Publication F... Page 41 of 41

Submit

Never submit passwords through Google Forms.

Powered by

This content is neither created nor endorsed by Google.

Report Abuse - Terms of Service - Additional Terms